2019 New Year Letter to Investors

Market release
20 February 2019


2019 New Year Letter to Investors


Dear Investors,

The 2018 calendar year was a very busy one for AFT Pharmaceuticals with continuing
progress on our pathway outlined at IPO.

Maxigesic Progress

We continue to make significant progress on multiple fronts.

In Australia, Maxigesic® continues to maintain its leading market share position over the
next paracetamol-ibuprofen combination product*. In New Zealand, the potential
reclassification of codeine to a prescription medicine similar to the decision which came into
effect 1 February 2018 in Australia remains a key opportunity for AFT. In Australia this
resulted in a significant increase in Maxigesic tablet sales and, if it occurs, a similar result in
New Zealand would be expected.

On the international front, we are increasing sales with a significant number of launch orders
received with the most recent being Belgium, Denmark, Finland, Iceland, Luxembourg,
Kuwait, Norway, Portugal, Spain and Sweden.

We expect the first registration of the new Maxigesic IV dose form this calendar year and we
are preparing further regulatory applications in major markets.

We also are now close to receiving our first Maxigesic sales milestone payment from a
licensee which will be around NZ$800,000. Our current licensing agreements in many cases
provide for sales milestones and this represents our first realization of this potential
multimillion-dollar income stream.

We have successfully completed the significant part of our clinical development program for
Maxigesic oral dose forms. The first regulatory filings have also been made for Maxigesic Oral
Solution, the pediatric dose form. Expanding the range of Maxigesic products, together with
increasing the number of countries in which we have launched, will likely be a significant
future driver of Maxigesic International sales.

We expect registration of Maxigesic tablets to be completed in the USA during the FY20
financial year, which would represent a significant milestone.

Licensing Update

This continues to progress with multiple term sheets or agreements currently under
negotiation.

We have also finalized an agreement in Cyprus for oral Maxigesic dose forms. We are
negotiating additional agreements and remain confident that additional deals will continue
to be made, especially for Maxigesic IV.

Progress in Asia: Significant Sales Increase Within Next 12 Months

Maxigesic® has been successfully launched in both Malaysia and Singapore. New Maxigesic
launches will fuel further growth with preparations well underway in Hong Kong following
partnering with DKSH Hong Kong. We have been impressed by their in-depth market
knowledge and extensive distribution network.

Agreements for Maxigesic in further Asian territories: Taiwan and Korea have been secured
in the last 6 months and further agreements are being worked on in Vietnam, Philippines
and Pakistan.

A further significant sales contract for a hospital product in Singapore has been secured and
additional contracts are under evaluation by key buyers in Singapore. Based upon existing
sales growth and new contracts secured, we are confident that sales will continue to
increase appreciably in Asia during the FY20 time period.

Return to Profitability

Historically AFT was profitable for many years prior to our anticipated significant R&D
investment utilizing capital raised at the IPO on both drug development and strengthening
our market position in Australia. As previously indicated, we remain on track to return to
EBITDA profit in the FY2019 financial year.
[End of Release]


For more information:

Dr Hartley Atkinson,
CEO, AFT Pharmaceuticals Ltd
Phone: +64 9 488 0232
Email: hartley@aftpharm.com







About MAXIGESIC®
MAXIGESIC® is a unique, patented combination of paracetamol and ibuprofen that provides
fast, effective double action pain relief from a wide range of pain.
https://www.aftpharm.com



About AFT
AFT is a growing multinational pharmaceutical business with a broad range of products, both
developed itself and in-licensed from third parties. AFT’s products cover all major
pharmaceutical distribution channels: over-the-counter, prescription and hospital.
Historically, AFT’s home markets have been Australia, New Zealand and South-East Asia.
However the company is out-licensing its own products to licensees and distributors to sell in
an increasing number of countries around the world. The company’s intensive Research and
Development programme forms the basis of its international sales strategy. For more
information about the company, visit
aftpharm.com


*Data source: IRi Total Australian Pharmacy Dollar Sales - MAT to 20/01/19.